Evidence map›Paper›PMID 39758221›Full record

ArticleThe Journal of clinical and aesthetic dermatology2024

Efficacy of Fractional 2940-nm Erbium:YAG Laser Combined with Platelet-Rich Plasma Versus its Combination with Low-Level Laser Therapy for Scar Revision.

Mai Abdelraouf Osman, Nevien Ahmed Samy, Ahmed Shami Jasim

Abstract read
In one paragraph

Article in The Journal of clinical and aesthetic dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mai Abdelraouf OsmanDrs. Osman and Samy are with the National Institute of Laser Enhanced Sciences (NIlES) in Giza Governorate, Egypt.
Nevien Ahmed SamyDrs. Osman and Samy are with the National Institute of Laser Enhanced Sciences (NIlES) in Giza Governorate, Egypt.
Ahmed Shami JasimDr. Jasim is with the Burn Center at Fallujah Teaching Hospital in Al Anbar Governorate, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: We sought to compare the safety and efficacy of combining fractional 2940-nm Erbium:YAG (Er:YAG) laser with autologous platelet-rich plasma (PRP) versus its combination with low-level laser therapy (LLLT) for enhancing the outcome of postsurgical and post-traumatic scars. Methods: Fourty-five individuals with post-surgical or post-traumatic scars were randomly divided into three groups: Group A received four fractional Er:YAG laser sessions spaced four weeks apart along with eight sessions of intradermal PRP injections spaced two weeks apart; Group B received four fractional Er:YAG laser sessions spaced four weeks apart along with two sessions of light emitting diode (LED) weekly; and Group C received four fractional Er:YAG laser sessions spaced four weeks apart. Treatment efficacy was evaluated using clinical photographs, Vancouver Scar Scale (VSS), patient satisfaction and histopathology. Results: Regarding vascularity following treatment and the total VSS score, there were significant differences between the studied groups, with scoring was the lowest in Group A compared to Group B and C. Patient satisfaction was the highest in Group A compared to Group B and C. Limitations: A limitation of the current study is the short follow-up period. Conclusion: Scar revision therapy using combined fractional Er:YAG laser with either PRP or LLLT were found to be more efficient and superior to fractional Er:YAG laser alone.

Indexed as

Fractional Er:YAG laserlow-level laser therapyPRPscar revision

Identifiers

PMID39758221
PMCPMC11694643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.